GlassScriptPhysician profile
Dat Quang Duong
NPI 1689740912
$16,378.65
in general payments reported to CMS, 2019-2025
28 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 95% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $1,270 · 2021: $2,462 · 2022: $2,527 · 2023: $2,301 · 2024: $3,502 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,150 · Travel and Lodging: $1.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,150.21 |
| Travel and Lodging | $1.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,295.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,499.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,393.70 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,313.88 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,280.01 | 2019-2025 | Jardiance |
| Abbvie INC. | $860.01 | 2019-2024 | Linzess, Creon, Viberzi |
| Gilead Sciences, INC. | $854.14 | 2019-2025 | Vemlidy |
| Lilly USA, LLC | $777.93 | 2019-2025 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $515.43 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $461.44 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $459.04 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $384.02 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $358.98 | 2019-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.41 | 2019-2024 | Xifaxan |
| Genzyme Corporation | $270.49 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $227.44 | 2021-2022 | |
| Abbott Laboratories | $178.47 | 2019-2025 | Freestyle Libre 3 |
| Redhill Biopharma INC. | $143.97 | 2024 | Talicia |
| Abiomed | $137.41 | 2025 | |
| Pfizer INC. | $133.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.25 | 2024 | |
| Sumitomo Pharma America, INC. | $89.54 | 2025 | Gemtesa |
| Astellas Pharma US INC | $79.74 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $79.37 | 2025 | Zenpep |
| Esperion Therapeutics, INC. | $37.90 | 2024-2025 | Nexletol |
| Genentech USA, INC. | $37.09 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $21.17 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dat Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.